Literature DB >> 1972574

The degradation of somatostatin by synaptic membrane of rat hippocampus is initiated by endopeptidase-24.11.

C Sakurada1, H Yokosawa, S Ishii.   

Abstract

Somatostatin was degraded by the synaptic membrane from rat hippocampus. Cleavage products were separated by reversed phase high performance liquid chromatography and identified by amino acid composition analyses and N-terminal amino acid and sequence determinations around the cleavage sites. Fragments produced from the cleavages at both or either sites between the Phe6-Phe7 and/or between the Thr10-Phe11, together with free phenylalanine and tryptophan, were major cleavage products, followed by that produced from the cleavage of the Asn5-Phe6 bond. The accumulation of the major cleavage products, as well as the initial cleavage of somatostatin, was strongly inhibited by metal chelators and also by specific inhibitors of endopeptidase-24.11 (EC 3.4.24.11), phosphoramidon and thiorphan. The inhibitor susceptibility of the synaptic membrane toward somatostatin was similar to that toward Leu-enkephalin, a natural substrate of endopeptidase-24.11. Furthermore, endopeptidase-24.11 purified from rat brain hydrolyzed somatostatin at the cleavage sites identical to those by the hippocampal synaptic membrane. Thus, it can be concluded that endopeptidase-24.11 plays a major role in the initial stage of somatostatin degradation in rat hippocampus.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1972574     DOI: 10.1016/0196-9781(90)90084-i

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  8 in total

1.  Major amyloid-β-degrading enzymes, endothelin-converting enzyme-2 and neprilysin, are expressed by distinct populations of GABAergic interneurons in hippocampus and neocortex.

Authors:  Javier Pacheco-Quinto; Christopher B Eckman; Elizabeth A Eckman
Journal:  Neurobiol Aging       Date:  2016-08-20       Impact factor: 4.673

Review 2.  Neprilysin inhibition: a new therapeutic option for type 2 diabetes?

Authors:  Nathalie Esser; Sakeneh Zraika
Journal:  Diabetologia       Date:  2019-05-14       Impact factor: 10.122

3.  Hydrolysis of somatostatin by human tissue kallikrein after the amino acid pair phe-Phe.

Authors:  D C Pimenta; M A Juliano; L Juliano
Journal:  Biochem J       Date:  1997-10-01       Impact factor: 3.857

4.  Pre- and post-natal ontogeny of neutral endopeptidase 24-11 ('enkephalinase') studied by in vitro autoradiography in the rat.

Authors:  I Dutriez; N Salès; M C Fournié-Zaluski; B P Roques
Journal:  Experientia       Date:  1992-03-15

5.  Hydrolysis of rat melanin-concentrating hormone by endopeptidase 24.11 (neutral endopeptidase).

Authors:  F Checler; P Dauch; H Barelli; J L Nahon; J P Vincent
Journal:  Biochem J       Date:  1992-08-15       Impact factor: 3.857

6.  Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice.

Authors:  William J Meilandt; Moustapha Cisse; Kaitlyn Ho; Tiffany Wu; Luke A Esposito; Kimberly Scearce-Levie; Irene H Cheng; Gui-Qiu Yu; Lennart Mucke
Journal:  J Neurosci       Date:  2009-02-18       Impact factor: 6.167

7.  Developmental Profile of Brain Neprilysin Expression Correlates with Olfactory Behaviour of Rats.

Authors:  Dimitrii S Vasilev; Nadezhda M Dubrovskaya; Igor A Zhuravin; Natalia N Nalivaeva
Journal:  J Mol Neurosci       Date:  2021-01-12       Impact factor: 3.444

8.  Trans-Modulation of the Somatostatin Type 2A Receptor Trafficking by Insulin-Regulated Aminopeptidase Decreases Limbic Seizures.

Authors:  Dimitri De Bundel; Assia Fafouri; Zsolt Csaba; Ellen Loyens; Sophie Lebon; Vincent El Ghouzzi; Stéphane Peineau; Guilan Vodjdani; Foteini Kiagiadaki; Najat Aourz; Jessica Coppens; Laura Walrave; Jeanelle Portelli; Patrick Vanderheyden; Siew Yeen Chai; Kyriaki Thermos; Véronique Bernard; Graham Collingridge; Stéphane Auvin; Pierre Gressens; Ilse Smolders; Pascal Dournaud
Journal:  J Neurosci       Date:  2015-08-26       Impact factor: 6.167

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.